GLUE
Monte Rosa Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.84
−3.76%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
Market Cap
$1.18B
MomentumView details →
1D Return
−3.76%
YTD Return
−10.65%
RSI (14)
36.3
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−3.8x
Market Cap
$1.18B
RSI (14)
36.3
MomentumView details →
1D Return
−3.76%
YTD Return
−10.65%
SummaryUpdated Jun 1, 2026
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Boston, Massachusetts. The company went public in June 2021 and specializes in developing innovative small molecule precision medicines that harness the body's natural protein degradation systems to treat cancer and immune-mediated diseases. Monte Rosa has emerged as a pioneer in the molecular glue degrader space, with multiple programs advancing through clinical development across oncology and immunology therapeutic areas.
Similar companies
Latest newsMore news →